Kymera Therapeutics, Inc.

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
82.21 ^USD	-2.71%		-4.50%	+5.65%

05-15	Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses	RE
05-12	Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09:20 AM

Kymera Therapeutics Q4 Loss Widens, Revenue Falls

Published on 02/26/2026 at 01:12 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Kymera Therapeutics, Inc.

05-15	Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses	RE
05-12	Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09:20 AM
05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI
04-30	Kymera Therapeutics, Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30	Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises	MT
04-30	Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss	MT
04-30	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M	MT
04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI
04-09	Kymera to Receive $45 Million Milestone Payment as Gilead Exercises Option to License KT-200	MT
04-09	Kymera Therapeutics announces Gilead Sciences' option exercise to license KT-200, oral CDK2 molecular glue degrader development candidate	RE
04-09	Kymera Therapeutics and Gilead Sciences Enter License Agreement for Kt-200 with $45 Million Milestone Payment	CI
03-28	Kymera Therapeutics Presents KT-621 BroADen Data In Late-Breaking Research Session At The American Academy Of Dermatology Annual Meeting	CI

Chart Kymera Therapeutics, Inc.

Duration

Period

KYMR: Dynamic Chart

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâ€™s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the bodyâ€™s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Employees

253

Sector

Biotechnology & Medical Research

More about the company